Aytu BioPharma Announces Business and Pipeline Progress and Reports Second Quarter 2022 Financial Results

14.02.2022 - Quarterly Net Revenue Increased 53% Year-over-year to $23.1 MillionPREVEnt Pivotal Study for AR101 in Vascular Ehlers-Danlos Syndrome On-track to Begin in Mid-2022Initiation of Randomized, Sham-controlled Study of Healight in Patients with ...

Related Keywords

United States ,Texas ,Grand Prairie ,Aytu Biopharma ,Mark Oki ,Chelcie Lister ,Josh Disbrow ,Aytu Venture Opportunities Fund ,Capital Group ,Drug Administration ,Research Development ,Deerfield Private Design Fund ,Nasdaq ,Exchange Commission ,Trademark Office ,Strategic Communications ,Venture Opportunities Fund ,Aytu Biopharma Inc ,Securities Exchange ,Second Quarter ,Orphan Drug Designation ,Orphan Drug Designation Granted ,Vascular Ehlers Danlos Syndrome ,Investigational New Drug ,Ehlers Danlos Syndrome ,Orphan Drug ,Light Catheter ,United States Patent ,Ultraviolet Therapy ,Financial Position ,Debt Refinancing ,Avenue Capital ,Avenue Venture Opportunities Fund ,Avenue Capital Group ,Deerfield Partners ,Chief Financial Officer ,First Half ,Earnings Before Interest ,Income Taxes ,United States Generally Accepted Accounting ,Full Prescribing Information ,Securities Act ,Securities Exchange Act ,Risk Factors ,Quarterly Reports ,Consolidated Statements ,